Sana Biotechnology’s (SANA) “Buy” Rating Reaffirmed at HC Wainwright

HC Wainwright reissued their buy rating on shares of Sana Biotechnology (NASDAQ:SANA) in a report released on Tuesday morning,Benzinga reports. The firm currently has a $11.00 price target on the stock.

Several other brokerages also recently commented on SANA. Citizens Jmp raised Sana Biotechnology from a “market perform” rating to an “outperform” rating and set a $5.00 target price on the stock in a report on Tuesday. TD Cowen raised Sana Biotechnology from a “hold” rating to a “buy” rating in a report on Wednesday, January 8th. Finally, Jefferies Financial Group initiated coverage on Sana Biotechnology in a report on Friday, March 14th. They issued a “buy” rating and a $7.00 target price on the stock. One investment analyst has rated the stock with a hold rating and six have given a buy rating to the stock. According to data from MarketBeat.com, Sana Biotechnology currently has an average rating of “Moderate Buy” and a consensus price target of $10.80.

Sana Biotechnology Trading Down 17.7 %

SANA stock opened at $2.28 on Tuesday. Sana Biotechnology has a 1-year low of $1.52 and a 1-year high of $10.50. The firm has a market cap of $509.05 million, a P/E ratio of -1.63 and a beta of 1.63. The business’s 50 day moving average is $3.06 and its 200-day moving average is $3.20.

Sana Biotechnology (NASDAQ:SANA) last announced its earnings results on Monday, March 17th. The company reported ($0.23) EPS for the quarter, topping the consensus estimate of ($0.25) by $0.02. Sell-side analysts forecast that Sana Biotechnology will post -1.16 EPS for the current year.

Insiders Place Their Bets

In other Sana Biotechnology news, insider Fmr Llc sold 290,912 shares of the company’s stock in a transaction on Wednesday, January 8th. The stock was sold at an average price of $6.49, for a total transaction of $1,888,018.88. Following the transaction, the insider now owns 4,541,511 shares of the company’s stock, valued at approximately $29,474,406.39. This represents a 6.02 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Company insiders own 31.10% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently bought and sold shares of SANA. Wilmington Savings Fund Society FSB bought a new stake in shares of Sana Biotechnology during the 3rd quarter valued at $29,000. Stifel Financial Corp bought a new stake in shares of Sana Biotechnology during the 3rd quarter valued at $43,000. EP Wealth Advisors LLC bought a new stake in shares of Sana Biotechnology during the 3rd quarter valued at $45,000. Tower Research Capital LLC TRC raised its position in shares of Sana Biotechnology by 229.9% during the 4th quarter. Tower Research Capital LLC TRC now owns 15,136 shares of the company’s stock valued at $25,000 after acquiring an additional 10,548 shares during the last quarter. Finally, Cerity Partners LLC bought a new stake in shares of Sana Biotechnology during the 4th quarter valued at $25,000. Institutional investors and hedge funds own 88.23% of the company’s stock.

Sana Biotechnology Company Profile

Sana Biotechnology, Inc, a biotechnology company, focuses on utilizing engineered cells as medicines. It develops ex vivo and in vivo cell engineering platforms for various therapeutic areas with unmet treatment needs, including oncology, diabetes, central nervous system disorders, B-cell-mediated autoimmune, and others.